90 related articles for article (PubMed ID: 26371431)
41. Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis?
Tong GX; Weeden EM; Hamele-Bena D; Huan Y; Unger P; Memeo L; O'Toole K
Am J Surg Pathol; 2008 Sep; 32(9):1380-7. PubMed ID: 18670350
[TBL] [Abstract][Full Text] [Related]
42. Immunohistochemistry for the novel markers glypican 3, PAX8, and p40 (ΔNp63) in squamous cell and urothelial carcinoma.
Gailey MP; Bellizzi AM
Am J Clin Pathol; 2013 Dec; 140(6):872-80. PubMed ID: 24225756
[TBL] [Abstract][Full Text] [Related]
43. PAX2 and PAX8: useful markers for metastatic effusions.
Waters L; Crumley S; Truong L; Mody D; Coffey D
Acta Cytol; 2014; 58(1):60-6. PubMed ID: 24334997
[TBL] [Abstract][Full Text] [Related]
44. p63, CK7, PAX8 and INI-1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high-grade tumours of the renal collecting system.
Carvalho JC; Thomas DG; McHugh JB; Shah RB; Kunju LP
Histopathology; 2012 Mar; 60(4):597-608. PubMed ID: 22260386
[TBL] [Abstract][Full Text] [Related]
45. Utility of PAX8 mouse monoclonal antibody in the diagnosis of thyroid, thymic, pleural and lung tumours: a comparison with polyclonal PAX8 antibody.
Toriyama A; Mori T; Sekine S; Yoshida A; Hino O; Tsuta K
Histopathology; 2014 Oct; 65(4):465-72. PubMed ID: 24592933
[TBL] [Abstract][Full Text] [Related]
46. PAX8 is expressed in anaplastic thyroid carcinoma diagnosed by fine-needle aspiration: a study of three cases with histological correlates.
Bellevicine C; Iaccarino A; Malapelle U; Sasso FC; Biondi B; Troncone G
Eur J Endocrinol; 2013 Sep; 169(3):307-11. PubMed ID: 23811186
[TBL] [Abstract][Full Text] [Related]
47. Malignant tumors with clear cell morphology: a comparative immunohistochemical study with renal cell carcinoma antibody, Pax8, steroidogenic factor 1, and brachyury.
Clayton EF; Ziober A; Yao Y; Bing Z
Ann Diagn Pathol; 2013 Apr; 17(2):192-7. PubMed ID: 23218904
[TBL] [Abstract][Full Text] [Related]
48. Cytoplasmic 5-Lipoxygenase Staining Is a Highly Sensitive Marker of Human Tumors of the Choroid Plexus.
Xingfu W; Lifeng Z; Yupeng C; Xueyong L; Wei L; Yinghao Y; Suqin C; Mi W; Sheng Z
Am J Clin Pathol; 2015 Aug; 144(2):295-304. PubMed ID: 26185315
[TBL] [Abstract][Full Text] [Related]
49. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas.
Marques AR; Espadinha C; Catarino AL; Moniz S; Pereira T; Sobrinho LG; Leite V
J Clin Endocrinol Metab; 2002 Aug; 87(8):3947-52. PubMed ID: 12161538
[TBL] [Abstract][Full Text] [Related]
50. Detection of PAX8 and p53 is beneficial in recognizing metastatic carcinomas in pelvic washings, especially in cases with suspicious cytology.
Xiang L; Zheng W; Kong B
Gynecol Oncol; 2012 Dec; 127(3):595-600. PubMed ID: 22940488
[TBL] [Abstract][Full Text] [Related]
51. Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study.
Tacha D; Zhou D; Cheng L
Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):293-9. PubMed ID: 21285870
[TBL] [Abstract][Full Text] [Related]
52. Expression, regulation, and function of paired-box gene 8 in the human placenta and placental cancer cell lines.
Ferretti E; Arturi F; Mattei T; Scipioni A; Tell G; Tosi E; Presta I; Morisi R; Lacroix L; Gulino A; Russo D; Damante G; Filetti S
Endocrinology; 2005 Sep; 146(9):4009-15. PubMed ID: 15961562
[TBL] [Abstract][Full Text] [Related]
53. Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon.
Boyd C; McCluggage WG
Am J Surg Pathol; 2012 Mar; 36(3):368-75. PubMed ID: 22082603
[TBL] [Abstract][Full Text] [Related]
54. Mesonephric adenocarcinomas of the uterine cervix and corpus: HPV-negative neoplasms that are commonly PAX8, CA125, and HMGA2 positive and that may be immunoreactive with TTF1 and hepatocyte nuclear factor 1-β.
Kenny SL; McBride HA; Jamison J; McCluggage WG
Am J Surg Pathol; 2012 Jun; 36(6):799-807. PubMed ID: 22456609
[TBL] [Abstract][Full Text] [Related]
55. Use of PAX8 and GATA3 in diagnosing sarcomatoid renal cell carcinoma and sarcomatoid urothelial carcinoma.
Chang A; Brimo F; Montgomery EA; Epstein JI
Hum Pathol; 2013 Aug; 44(8):1563-8. PubMed ID: 23453625
[TBL] [Abstract][Full Text] [Related]
56. OLIG2 is a useful immunohistochemical marker in differential diagnosis of clear cell primary CNS neoplasms.
Preusser M; Budka H; Rössler K; Hainfellner JA
Histopathology; 2007 Feb; 50(3):365-70. PubMed ID: 17257132
[TBL] [Abstract][Full Text] [Related]
57. Diagnostic algorithm for determining primary tumor sites using peritoneal fluid.
Park CK; Malinowski DP; Cho NH
PLoS One; 2018; 13(7):e0199715. PubMed ID: 30024911
[TBL] [Abstract][Full Text] [Related]
58. Diagnostic significance of PAX8 in thyroid squamous cell carcinoma.
Suzuki A; Hirokawa M; Takada N; Higuchi M; Yamao N; Kuma S; Daa T; Miyauchi A
Endocr J; 2015; 62(11):991-5. PubMed ID: 26354716
[TBL] [Abstract][Full Text] [Related]
59. PAX8 expression in human bladder cancer.
Pellizzari L; Puppin C; Mariuzzi L; Saro F; Pandolfi M; Di Lauro R; Beltrami CA; Damante G
Oncol Rep; 2006 Nov; 16(5):1015-20. PubMed ID: 17016586
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of PAX8 expression promotes the proliferation of stomach Cancer cells.
Bie LY; Li N; Deng WY; Lu XY; Guo P; Luo SX
BMC Mol Cell Biol; 2019 Dec; 20(1):61. PubMed ID: 31881968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]